News

December 19, 2018December 19, 2018

Protagonist Therapeutics Starts Phase 1 Trial of Potential Ulcerative Colitis Treatment PN-10943

News

Protagonist Therapeutics has begun dosing patients in a Phase 1 clinical trial of an oral ulcerative colitis (UC) treatment candidate known as PN-10943, the company announced in a press release. PN-10943 ... Read more

December 14, 2018December 14, 2018

Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment

News

Janssen Biotech will conduct a Phase 1 clinical trial in healthy volunteers to test VE202, an investigational oral treatment for inflammatory bowel disease (IBD), Vedanta Biosciences has announced. In 2015, Janssen ... Read more

December 12, 2018December 12, 2018

Second Annual IBDHorizons Conference Will Focus on IBD Management

News

The second annual IBDHorizons (IBDH) Conference will focus on inflammatory bowel disease (IBD) management and include a host of renowned experts. The conference, set for Feb. 23 in Columbus, Ohio, ... Read more

December 5, 2018December 5, 2018

Potential IBD Therapy PTG-200 Safe, Well-tolerated in Healthy Volunteers, Phase 1 Results Show

News

PTG-200, being developed by Protagonist Therapeutics in collaboration with Janssen Biotech for the treatment of moderate and severe Crohn’s disease, was found safe and well-tolerated in healthy volunteers, according to top-line results ... Read more

November 28, 2018November 28, 2018

Cosentyx May Increase Risk for Inflammatory Bowel Disease, Italian Researchers Say

News

Italian researchers are calling attention to what they say is an alarming number of newly diagnosed cases of inflammatory bowel disease (IBD) in people treated with the human monoclonal ... Read more

November 16, 2018November 16, 2018

Crohn’s and Ulcerative Colitis Prevalence in Canada — Already High — Will Almost Double by 2030, Report Warns

News

Canada has the world’s highest prevalence of the two main forms of inflammatory bowel disease (IBD) — Crohn’s disease and ulcerative colitis — and the incidence of IBD is increasing ... Read more

November 12, 2018November 12, 2018

FDA Approves Humira Biosimilar Hyrimoz for Treatment of IBD, Other Conditions

News

The U.S. Food and Drug Administration (FDA) approved Hyrimoz (adalimumab-adaz, by Sandoz), a biosimilar to AbbVie’s Humira (adalimumab) for the treatment of Crohn’s disease (CD) in adults and ulcerative colitis (UC). A ... Read more

November 5, 2018November 5, 2018

Cannabis Oil Eases Symptoms of Crohn’s Disease But Not Gut Inflammation, Scientists Report

News

Cannabis oil significantly reduced the symptoms of Crohn’s disease and improved patients’ quality of life, but did not ease the underlying gut inflammation as was expected, researchers in Israel reported. These results ... Read more

November 2, 2018November 2, 2018

Antibiotic Use May Promote IBD Development by Disrupting Gut Immune Cells, Mouse Study Suggests

News

Antibiotics can disrupt immune cells residing in the gut, triggering the rise of pro-inflammatory cells and reducing healthy bacteria — two steps key in the development of inflammatory bowel ... Read more

October 31, 2018October 31, 2018

Depression Raises Risk of IBD, but Antidepressants May Have Protective Effect, Study Finds

News

People diagnosed with depression have a higher risk of Crohn’s disease and ulcerative colitis, but taking antidepressants may protect against the development of these inflammatory bowel diseases, a British study ... Read more

Pin It on Pinterest